Market Size & Trends
The U.S. Alzheimer’s-linked imaging market size was estimated at USD 4.49 billion in 2024 and is projected to reach USD 6.90 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033. Market growth is mainly driven by the rising number of Alzheimer’s cases across the country. According to the National Library of Medicine (NLH) (2024), around 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this number could reach 13.8 million by 2060 if no breakthrough occurs. Alzheimer’s is now the fifth-leading cause of death among older adults in the U.S., highlighting its growing public health impact.
As the prevalence of the disease increases, demand for early diagnosis and continuous monitoring is rising. This is creating strong opportunities for investment and innovation in Alzheimer’s-related imaging technologies and services. Government and public health agencies are also supporting this trend. For instance, the Centers for Disease Control and Prevention’s (CDC) Alzheimer’s disease Program promotes awareness, early detection, and diagnostic readiness. Together, these initiatives are helping expand diagnostic infrastructure, improve access to imaging services, and encourage technological advancements in brain-disease imaging across the U.S.
Furthermore, a study by Rush University highlighted significant regional differences in Alzheimer’s disease prevalence across the U.S., with the highest rates observed in states such as Florida and Maryland. These county-level variations are influenced by factors such as population age distribution, socioeconomic conditions, healthcare accessibility, and lifestyle habits.
Technological advancements continue to drive the growth of the U.S. Alzheimer’s-linked imaging industry. Currently used techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), are essential methods for the diagnosis and monitoring of Alzheimer’s disease. MRI provides excellent anatomical imaging, PET allows visualization and quantification of amyloid-β plaques and tau tangles, and SPECT assesses cerebral blood flow and deficits in brain function. These techniques are routinely used to plan diagnosis and treatment in hospitals and outpatient imaging centers throughout the U.S.
AI-assisted diagnostics are transforming the U.S. Alzheimer’s-linked imaging market. For instance, Mayo Clinic’s StateViewer AI can detect nine types of dementia, including Alzheimer’s, from a single fluorodeoxyglucose positron emission tomography (FDG-PET) scan. By enhancing accuracy and reducing interpretation time, AI expands access to advanced diagnostics and boosts confidence in early, precise detection across clinical settings.
Furthermore, strong governmental support and strategic planning exist within the market. For instance, the National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, oversees all federal activities aimed at addressing Alzheimer's disease (AD) and related dementias. The National Alzheimer's Project Act (NAPA) established the National Plan to Address Alzheimer's Disease, which aims to accelerate research, treatment, and support patients, families, and caregivers on various related topics. The plan's primary focus is on improving early detection, enhancing patient care and the caregiver experience, expanding effective care models, and advancing research in diagnosis and treatment. These initiatives reflect the U.S. government’s commitment to strengthening Alzheimer’s care infrastructure and research capacity, fostering wider adoption of advanced diagnostic and imaging technologies, and supporting growth in the Alzheimer’s-linked imaging market.
U.S. Alzheimer’s-linked Imaging Market Report Segmentation
This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segment from 2021 to 2033. For this study, the analyst has segmented the U.S. Alzheimer’s-linked imaging market report based on imaging modality, and end use:Imaging Modality Outlook (Revenue, USD Million, 2021-2033)
- Positron Emission Tomography
- Magnetic Resonance Imaging
- Single Photon Emission Computed Tomography
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals & Clinics
- Diagnostic Imaging Centers
- Contract Research Organizations (CROs)
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Alzheimer’s-linked Imaging Market Variables, Trends & Scope
Chapter 4. U.S. Alzheimer’s-linked Imaging Market: Imaging Modality Estimates & Trend Analysis
Chapter 5. U.S. Alzheimer’s-linked Imaging Market: End Use Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this U.S. Alzheimer’s-linked Imaging market report include:- GE Healthcare
- Siemens Healthineers AG
- Life Molecular Imaging (LMI)
- Eli Lilly and Company
- SOFIE Biosciences
- Lantheus Holdings, Inc.
- Jubilant Radiopharma
- Brainreader A/S/ Neuroreader
- Koninklijke Philips N.V.
- Alzevita
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | November 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 4.49 Billion |
| Forecasted Market Value ( USD | $ 6.9 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
